MindMed reports Q1 cash $245.5M; Phase 3 trials on track for 2026 topline data

Definium Therapeutics, Inc.

2025-Q1 EPS reported -$0.35

Cash and investments $245.5M at March 31, 2025; runway into 2027 and at least 12 months beyond first Phase 3 readout.
Dosed first patient in Phase 3 Emerge study of MM120 ODT for MDD; topline data expected 2H 2026.
Enrollment on track in Phase 3 Voyage and Panorama studies for GAD; topline data 1H 2026 (Voyage) and 2H 2026 (Panorama).
Amended K2 HealthVentures loan: up to $120M available, received ~$17.8M net cash, interest-only period extended through May 1, 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.